Updated Story Remdesivir is worth up to $4,500 for each patient, according to the Institute for Clinical and Economic Review, and that initial estimate kicks off the debate over pandemic drug prices. This also could be the week that CMS announces a plan to lower insulin costs for seniors. Plus, hospitals expect the agency to propose a rule that could include reimbursement policy for expensive CAR-T cancer drugs. Gilead’s remdesivir is the first drug to show real...